SCIENCE & SOURCES
FOUNDATION · THE ENDOCANNABINOID SYSTEM
The foundation. The endocannabinoid system.
The endocannabinoid system (ECS) is a master regulatory network of receptors (CB1, CB2, TRPV1, PPARγ, GPR55), endogenous ligands (anandamide, 2-AG), and enzymes (FAAH, MAGL). Present in nervous tissue, gut lining, immune cells, endocrine glands, adipose tissue, and mitochondria. Its function is widely understood as homeostatic — keeping balance across other physiological systems. WHAT WE SAY ON THIS SITE — "CBD interacts with the endocannabinoid system, a regulatory network across multiple body systems." 01. Lu, H-C. & Mackie, K. (2016). An Introduction to the Endogenous Cannabinoid System. Biological Psychiatry, 79(7): 516–525. 02. Lu, H-C. & Mackie, K. (2021). Review of the Endocannabinoid System. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 6(6): 607–615. 03. Pacher, P. & Kunos, G. (2013). Modulating the endocannabinoid system in human health and disease. FEBS Journal, 280(9): 1918–1943. 04. Di Marzo, V. (2018). New approaches and challenges to targeting the endocannabinoid system. Nature Reviews Drug Discovery, 17(9): 623–639. 05. Russo, E. B. (2016). Beyond Cannabis: Plants and the Endocannabinoid System. Trends in Pharmacological Sciences, 37(7): 594–605. 06. Mechoulam, R. & Parker, L. A. (2013). The endocannabinoid system and the brain. Annual Review of Psychology, 64: 21–47. 07. Russo, E. B. (2004). Clinical endocannabinoid deficiency (CECD). Neuro Endocrinology Letters, 25(1–2): 31–39. Hypothesis 08. Russo, E. B. (2016). Clinical Endocannabinoid Deficiency Reconsidered. Cannabis and Cannabinoid Research, 1(1): 154–165. Hypothesis
CALM · NERVOUS SYSTEM
The case for calm.
CBD acts as a partial agonist at the 5-HT1A serotonin receptor, modulates GABA-A receptor activity, inhibits fatty acid amide hydrolase (raising anandamide), and engages TRPV1 receptors involved in stress signalling. WHAT WE SAY ON THIS SITE — "Research suggests CBD interacts with GABA and serotonin (5-HT1A) receptors, which are involved in the body's stress and calm response." 01. Russo, E. B., et al. (2005). Agonistic properties of cannabidiol at 5-HT1A receptors. Neurochemical Research, 30(8): 1037–1043. 02. Bakas, T., et al. (2017). The direct actions of cannabidiol and 2-arachidonoyl glycerol at GABA-A receptors. Pharmacological Research, 119: 358–370. 03. Bisogno, T., et al. (2001). Molecular targets for cannabidiol and its synthetic analogues. British Journal of Pharmacology, 134(4): 845–852. 04. Bergamaschi, M. M., et al. (2011). Cannabidiol reduces anxiety in social phobia patients. Neuropsychopharmacology, 36(6): 1219–1226. Human · RCT 05. Linares, I. M., et al. (2019). Cannabidiol presents an inverted U-shaped dose-response curve. Brazilian Journal of Psychiatry, 41(1): 9–14. Human 06. Crippa, J. A. S., et al. (2011). Neural basis of anxiolytic effects of cannabidiol in generalized social anxiety disorder. Journal of Psychopharmacology, 25(1): 121–130. Human 07. Shannon, S., et al. (2019). Cannabidiol in anxiety and sleep: a large case series. The Permanente Journal, 23: 18–041. Human
BALANCE · HORMONAL SYSTEM (HPA AXIS)
The case for balance.
The HPA axis is the central stress-response pathway. CB1 receptors are expressed throughout HPA tissues; endocannabinoid signalling exerts inhibitory control over HPA activation. CBD has been shown in human studies to dampen cortisol response. WHAT WE SAY ON THIS SITE — "Research links the endocannabinoid system to the HPA axis, the pathway that governs the body's cortisol response." 01. Zuardi, A. W., et al. (1993). Effect of cannabidiol on plasma prolactin, growth hormone and cortisol in human volunteers. Brazilian Journal of Medical and Biological Research, 26(2): 213–217. Human 02. Hill, M. N. & Tasker, J. G. (2012). Endocannabinoid signaling, glucocorticoid-mediated negative feedback and regulation of the HPA axis. Neuroscience, 204: 5–16. 03. Patel, S., et al. (2017). The endocannabinoid system as a target for novel anxiolytic drugs. Neuroscience and Biobehavioral Reviews, 76: 56–66. 04. Appiah-Kusi, E., et al. (2020). Effects of short-term cannabidiol treatment on response to social stress. Psychopharmacology, 237(4): 1121–1130. Human · RCT
FOCUS · COGNITIVE PERFORMANCE
The case for focus.
The most-cited paper underneath our cognitive framing is a 2020 University College London arterial-spin-labelling MRI study: a single dose of CBD increased blood flow to the hippocampus, a region central to memory. Matcha science adds a second layer in Precision only — caffeine paired with L-theanine for alert calm. WHAT WE SAY ON THIS SITE — "A 2020 paper in the Journal of Psychopharmacology found a single dose of CBD increased blood flow to the hippocampus, a region central to memory." 01. Bloomfield, M. A. P., et al. (2020). The effects of acute cannabidiol on cerebral blood flow and memory. Journal of Psychopharmacology, 34(9): 981–989. Human · RCT · UCL 02. Hindocha, C., et al. (2015). Acute effects of THC, CBD and their combination on facial emotion recognition. European Neuropsychopharmacology, 25(3): 325–334. Human 03. Solowij, N., et al. (2019). A randomised controlled trial of vaporised THC and CBD. European Archives of Psychiatry and Clinical Neuroscience, 269(1): 17–35. Human · RCT 04. Crippa, J. A., et al. (2018). Translational investigation of the therapeutic potential of cannabidiol. Frontiers in Immunology, 9: 2009. 05. Iseger, T. A. & Bossong, M. G. (2015). A systematic review of the antipsychotic properties of cannabidiol in humans. Schizophrenia Research, 162(1-3): 153–161. 06. Owen, G. N., et al. (2008). The combined effects of L-theanine and caffeine on cognitive performance and mood. Nutritional Neuroscience, 11(4): 193–198. Human · Matcha 07. Mason, R. (2001). 200 mg of Zen: L-theanine boosts alpha waves. Alternative & Complementary Therapies, 7(2): 91–95.
GUT · GUT–BRAIN AXIS
The case for gut.
The ECS is densely expressed in the gut — enteric neurons, immune cells of the lamina propria, and the epithelium itself. The gut-brain axis is regulated bidirectionally through vagal signalling and microbiome-derived metabolites. Acacia prebiotic fibre adds a separate evidence layer. WHAT WE SAY ON THIS SITE — "Emerging studies suggest CBD may support intestinal barrier function and the gut microbiome." 01. Couch, D. G., et al. (2018). The use of cannabinoids in colitis: a systematic review and meta-analysis. Inflammatory Bowel Diseases, 24(4): 680–697. 02. Alhouayek, M. & Muccioli, G. G. (2012). The endocannabinoid system in inflammatory bowel diseases. Trends in Molecular Medicine, 18(10): 615–625. 03. De Filippis, D., et al. (2011). Cannabidiol reduces intestinal inflammation through the control of neuroimmune axis. PLoS ONE, 6(12): e28159. 04. Cluny, N. L., et al. (2015). Prevention of diet-induced obesity effects on body weight and gut microbiota. PLoS ONE, 10(12): e0144270. 05. Mehrpouya-Bahrami, P., et al. (2017). Blockade of CB1 cannabinoid receptor alters gut microbiota. Scientific Reports, 7(1): 15645. 06. Storr, M. A., et al. (2008). The role of the endocannabinoid system in the pathophysiology and treatment of irritable bowel syndrome. Neurogastroenterology and Motility, 20(8): 857–868. 07. Calame, W., et al. (2008). Gum arabic establishes prebiotic functionality in healthy human volunteers. British Journal of Nutrition, 100(6): 1269–1275. Human · Acacia
ENERGY · CELLULAR METABOLISM
The case for energy.
PPARγ is a nuclear receptor central to fat metabolism, insulin sensitivity, and mitochondrial biogenesis. TRPV1 modulates cellular energy expenditure via PGC-1α. CBD engages both. Cordyceps sinensis — one of the seven mushrooms in every Ritual — adds two human exercise-tolerance studies. WHAT WE SAY ON THIS SITE — "Preclinical research suggests CBD interacts with PPARγ and TRPV1 pathways, both involved in cellular energy regulation." 01. O'Sullivan, S. E. (2016). An update on PPAR activation by cannabinoids. British Journal of Pharmacology, 173(12): 1899–1910. 02. Ryberg, E., et al. (2007). The orphan receptor GPR55 is a novel cannabinoid receptor. British Journal of Pharmacology, 152(7): 1092–1101. 03. Costa, B., et al. (2004). Vanilloid TRPV1 receptor mediates the antihyperalgesic effect of cannabidiol. British Journal of Pharmacology, 143(2): 247–250. 04. Parray, H. A. & Yun, J. W. (2016). Cannabidiol promotes browning in 3T3-L1 adipocytes. Molecular and Cellular Biochemistry, 416(1-2): 131–139. 05. Bielawiec, P., et al. (2020). Phytocannabinoids: useful drugs for the treatment of obesity? Frontiers in Endocrinology, 11: 114. 06. Hirsch, K. R., et al. (2017). Cordyceps militaris improves tolerance to high-intensity exercise. Journal of Dietary Supplements, 14(1): 42–53. Human · Cordyceps 07. Chen, S., et al. (2010). Effect of Cs-4® (Cordyceps sinensis) on exercise performance in healthy older subjects. Journal of Alternative and Complementary Medicine, 16(5): 585–590. Human · RCT · Cordyceps
THE INGREDIENTS
The ingredients. Every one, receipted.
◆ CACAO · THEOBROMA CACAO EFSA permits general nutrition claims for cacao's contribution to magnesium, iron, and potassium intake under Regulation (EC) No 1924/2006. We frame cacao by heritage, mineral profile, and depth — never by what one gram of cacao does in the finished cup. We do not use the word "flavanols" in consumer copy: the EFSA Article 13 cocoa-flavanol claim sits at 200 mg per day, far outside our serving level. ◆ THE SEVEN MUSHROOMS Chaga, reishi, tremella, shiitake, maitake, cordyceps sinensis, lion's mane — every gram is fruiting-body extract at a 20:1 ratio. Below, the research behind each one, graded honestly: human trials are tagged, laboratory and animal work is named as such, and where the evidence is still early, we say so. ◆ LION'S MANE · HERICIUM ERINACEUS Studied in small human trials for cognitive function. The nerve-growth-factor mechanism is laboratory-stage. 01. Mori, K., et al. (2009). Improving effects of the mushroom Yamabushitake (Hericium erinaceus) on mild cognitive impairment: a double-blind placebo-controlled clinical trial. Phytotherapy Research, 23(3): 367–372. Human · RCT 02. Nagano, M., et al. (2010). Reduction of depression and anxiety by 4 weeks Hericium erinaceus intake. Biomedical Research, 31(4): 231–237. Human · RCT 03. Docherty, S., et al. (2023). The Acute and Chronic Effects of Lion's Mane Mushroom Supplementation on Cognitive Function, Stress and Mood in Young Adults. Nutrients, 15(22): 4842. Human · RCT · Pilot ◆ REISHI · GANODERMA LUCIDUM Studied in human trials for fatigue and wellbeing. Traditional use for calm; no human sleep trial exists, and we don't claim one. 01. Tang, W., et al. (2005). A randomized, double-blind and placebo-controlled study of a Ganoderma lucidum polysaccharide extract in neurasthenia. Journal of Medicinal Food, 8(1): 53–58. Human · RCT 02. Zhao, H., et al. (2012). Spore powder of Ganoderma lucidum improves cancer-related fatigue in breast cancer patients undergoing endocrine therapy. Evidence-Based Complementary and Alternative Medicine, 2012: 809614. Human · Pilot ◆ CORDYCEPS · CORDYCEPS SINENSIS The strongest human evidence in the stack — two exercise-tolerance trials, cited under Pillar 05 · Energy above. ◆ CHAGA · INONOTUS OBLIQUUS Studied in laboratory research for antioxidant activity. No human ingestion trials exist — so we say "studied in laboratory research," and nothing more. 01. Park, Y. K., et al. (2004). Chaga mushroom extract inhibits oxidative DNA damage in human lymphocytes as assessed by comet assay. BioFactors, 21(1–4): 109–112. In vitro 02. Najafzadeh, M., et al. (2007). Chaga mushroom extract inhibits oxidative DNA damage in lymphocytes of patients with inflammatory bowel disease. BioFactors, 31(3–4): 191–200. In vitro 03. Glamočlija, J., et al. (2015). Chemical characterization and biological activity of Chaga (Inonotus obliquus). Journal of Ethnopharmacology, 162: 323–332. In vitro ◆ MAITAKE · GRIFOLA FRONDOSA Defined by its beta-glucan content. Human metabolic evidence is preliminary; the systematic review below says exactly that, and so do we. 01. Ulbricht, C., et al. (2009). Maitake mushroom (Grifola frondosa): systematic review by the Natural Standard Research Collaboration. Journal of the Society for Integrative Oncology, 7(2): 66–72. Systematic review 02. Deng, G., et al. (2009). A phase I/II trial of a polysaccharide extract from Grifola frondosa (Maitake mushroom) in breast cancer patients: immunological effects. Journal of Cancer Research and Clinical Oncology, 135(9): 1215–1221. Human · Phase I/II 03. Konno, S., et al. (2001). A possible hypoglycaemic effect of maitake mushroom on Type 2 diabetic patients. Diabetic Medicine, 18(12): 1010. Human · Observation ◆ SHIITAKE · LENTINULA EDODES Studied in a randomised human trial for immune function, and in animal work for the gut microbiome. 01. Dai, X., et al. (2015). Consuming Lentinula edodes (Shiitake) mushrooms daily improves human immunity: a randomized dietary intervention in healthy young adults. Journal of the American College of Nutrition, 34(6): 478–487. Human · RCT 02. Xu, X., et al. (2015). Lentinula edodes-derived polysaccharide alters the spatial structure of gut microbiota in mice. PLoS ONE, 10(1): e0115037. Animal 03. Xu, X. & Zhang, X. (2015). Lentinula edodes-derived polysaccharide rejuvenates mice in terms of immune responses and gut microbiota. Food & Function, 6(8): 2653–2663. Animal ◆ TREMELLA · TREMELLA FUCIFORMIS Studied for its moisture-binding polysaccharides and antioxidant action — review-level and laboratory evidence; no human skin trial exists, and we don't imply one. 01. Wu, Y-J., et al. (2019). Structure, bioactivities and applications of the polysaccharides from Tremella fuciformis mushroom: a review. International Journal of Biological Macromolecules, 121: 1005–1010. Review 02. Ma, X., et al. (2021). A review on the production, structure, bioactivities and applications of Tremella polysaccharides. International Journal of Immunopathology and Pharmacology, 35. Review ◆ GENERAL MUSHROOM REFERENCES 01. Powell, M. (2014). Medicinal Mushrooms — A Clinical Guide. Mycology Press. Textbook 02. Stamets, P. & Zwickey, H. (2014). Medicinal Mushrooms: Ancient Remedies Meet Modern Science. Integrative Medicine, 13(1): 46–47. ◆ SHILAJIT Studied in human trials for strength retention under fatigue and hormonal markers; its mineral–fulvic acid profile is review-level science. 01. Stohs, S. J. (2014). Safety and efficacy of shilajit (mumie, moomiyo). Phytotherapy Research, 28(4): 475–479. Review 02. Keller, J. L., et al. (2019). The effects of shilajit supplementation on fatigue-induced decreases in muscular strength and serum hydroxyproline levels. Journal of the International Society of Sports Nutrition, 16: 3. Human · RCT 03. Carrasco-Gallardo, C., Guzmán, L. & Maccioni, R. B. (2012). Shilajit: a natural phytocomplex with potential procognitive activity. International Journal of Alzheimer's Disease, 2012: 674142. 04. Pandit, S., et al. (2016). Clinical evaluation of purified shilajit on testosterone levels in healthy volunteers. Andrologia, 48(5): 570–575. Human · RCT · Trade context only ◆ CAYENNE · CAPSICUM ANNUUM The finishing whisper in every Ritual — and the best-evidenced ingredient per milligram. Two systematic reviews and a human crossover trial support capsaicin's modest thermogenic effect. We say "studied for thermogenesis" — we do not claim it enhances the absorption of other ingredients, because that evidence belongs to black pepper, not cayenne. 01. Ludy, M-J., Moore, G. E. & Mattes, R. D. (2012). The effects of capsaicin and capsiate on energy balance: critical review and meta-analyses of studies in humans. Chemical Senses, 37(2): 103–121. Meta-analysis · Human 02. Whiting, S., Derbyshire, E. & Tiwari, B. K. (2012). Capsaicinoids and capsinoids: a potential role for weight management? A systematic review of the evidence. Appetite, 59(2): 341–348. Systematic review 03. Janssens, P. L., et al. (2013). Acute effects of capsaicin on energy expenditure and fat oxidation in negative energy balance. PLoS ONE, 8(7): e67786. Human · RCT
OUR LANGUAGE MAP
How we talk about it.
The line between food and medicine is a regulated one. Every phrase below is a deliberate choice. "Research suggests" — Multiple peer-reviewed papers — on the mechanism, not necessarily on the finished product. (Mechanism) "Studied for…" — Published research exists on that mechanism or outcome — graded honestly on this page, with human trials tagged. (Graded evidence) "Designed to support" — The ingredient is paired with the system based on its known mechanism. (Structure/function) "A 2020 study found…" — A specific named paper, listed on this page. (Direct citation) "Long-used in traditional practice" — Ethnobotanical / traditional-use frame — not a modern clinical claim. (Heritage) "Cures · treats · prevents · guarantees" — Never used. These are words for licensed medicines. (—) "Flavanols" — Never used in consumer copy. The EFSA claim sits at 200 mg/day — far beyond our serving. (—)